secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001683168-22-006716
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health dissolves sports advisory board, provides concussion drug update: Phase I complete, Phase II planned
--------------------------------------------------------------------------------

- Dissolved sports advisory board to eliminate distraction and maintain focus on drug development.
- Phase I human trial completed; drug proven safe and well tolerated.
- Company plans to initiate Phase II trial to evaluate efficacy and safety in concussed patients.
- Company states it has never received government funding; drug development funded by accredited investors.
- Intellectual property and rights to the drug purchased on March 1, 2021 from a third party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/0001683168-22-006716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822006716/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-006716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer